GL Pharm Tech Corp (204840)

Overview

GL Pharm Tech Corp., headquartered in Seongnam-si, South Korea, is a prominent provider in the pharmaceutical industry, specializing in the development, production, and supply of generic drugs and incrementally modified drug (IMD) formulation technologies. Since its establishment in 2002, the company has been dedicated to offering advanced pharmaceutical solutions primarily to companies within South Korea. Its portfolio stretches across various therapeutic categories, including cardiovascular, urology, pain management, anti-infection, gastric disease, diabetes, central nervous system disorders, respiratory diseases, and transplantation among others. In addition to its generic and IMD offerings, GL Pharm Tech Corp. invests in the development of new molecule entity pipeline products targeting conditions such as dry eye disease, underpinning its commitment to innovation and therapeutic advancement.

Products and Services

• Incrementally Modified Drug (IMD) Formulation Technology

  GL Pharm Tech provides IMD formulation technology targeting several indictments like gastritis, antidepressants, anorectics, and antibiotics. This technology aims to enhance the efficacy, safety, and patient compliance of existing drug molecules, offering pharmaceutical companies avenues for product differentiation and extended product lifecycle.

• Generic Drugs

  The company manufactures and supplies a wide range of generic drugs encompassing treatments for cardiovascular diseases, urology, pain management, anti-infections, gastric diseases, diabetes, central nervous system diseases, respiratory diseases, and transplantation. These offerings underscore GL Pharm Tech's role in increasing access to essential medicines across various therapeutic areas.

• New Molecule Entity Pipeline Products

  Focused on the discovery and development of novel therapies, GL Pharm Tech Corp. is working on pipeline products for conditions such as dry eye disease. This initiative reflects the company's commitment to contributing to the global healthcare landscape through innovation.

• Specific Pharmaceutical Products
  • Cabalin CR Extended-release Tablet

    Designed for the nervous system and sensory organs, Cabalin CR features an extended-release formulation aimed at improving patient compliance and therapeutic outcomes.

  • Jample Ibufen Syrup

    A treatment option for the nervous system and sensory organs, Jample Ibufen Syrup is indicated for various conditions, providing a user-friendly oral administration form.

  • Gisoren Tablets

    These tablets are targeted at treating individual organs, specifically within the digestive system and peptic ulcer disease, showcasing GL Pharm Tech's focus on gastroenterological conditions.

  • Genstring Troki

    Genstring Troki is tailored for the treatment of individual organs and digestive system conditions, available for oral use. It represents the company's effort in offering specialized therapeutic options.